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Abstract
Background: Acute pancreatitis is a potentially lethal disease, with a rising incidence in the Western world. Yet, no
pharmacological prevention or specific treatment for acute pancreatitis exists. Also, the connection with severity of
acute pancreatitis is unknown. Experimental and epidemiological research suggests a protective effect of
angiotensin II receptor blockers.
Methods: During 2006 to 2008, we performed a nationwide case–control study on Swedish residents aged 40–84
years. First-time cases with acute pancreatitis were identified in the National Patient Register and data on dispensed
prescriptions was retrieved from the Prescribed Drug Register. Controls were randomly selected from the general
population in Sweden frequency-matched on sex, age, and calendar year. To estimate relative risk of acute
pancreatitis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-users, we
used multivariable logistic regression analysis to calculate odds ratios (OR) with 95% confidence interval (CI).
Results: Among 6,161 cases of acute pancreatitis and 61,637 controls, current use of angiotensin II receptor blockers
was followed by a decreased risk of acute pancreatitis, compared to non-users, adjusted OR 0 · 77 (95% CI 0 · 69–0 · 86).
No protective association, but an increased risk was found for users of angiotensin-converting enzyme inhibitors
(adjusted OR 1 · 11, 95% CI: 1 · 01–1 · 21), analysed for comparison reasons. There was a significant decreased risk
associated with both severe acute pancreatitis, (OR 0 · 71 (0 · 59–0 · 85), and mild acute pancreatitis; adjusted OR 0 · 81
(0 · 70–0 · 94).
Conclusion: This population-based case–control study indicates that use of angiotensin II receptor blockers might be
associated with a lesser risk of acute pancreatitis, and that the protective association was significant among cases of
both severe and mild acute pancreatitis.
Keywords: Pancreas, Inflammation, Pharmacoepidemiology, Metabolic syndrome, Risk factors, Drugs, Hypertension,
Prevention
Background
Pharmacological prevention of acute pancreatitis is
warranted. Acute pancreatitis accounts for considerable
morbidity and health care costs in Western countries.
The reported incidence ranges between 5 and 70 per
100,000 persons per year, with an unexplained rising
trend in several Western countries during the last
decades [1–3]. The major risk factors, gallstone disease
and excessive alcohol consumption, together account for
about 2/3 of the cases [3–7]. Other risk factor include
drugs, some viral infections and other uncommon
reasons like endoscopic manipulation of the bile duct,
leaving about 20% of the causes to the cases remain
unexplained. A number of drugs have also been claimed
to increase the risk of acute pancreatitis [8], e.g., valproate,
[9] tetracycline, [10, 11] and 5-aminosalicylic acid [12].
Pharmacological prevention has been studied, especially
of acute pancreatitis caused by endoscopic retrograde
cholangio-pancreatography (ERCP), but without clinical
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success [13]. Angiotensin II receptor blockers (ARB) are
often used to treat hypertension and heart failure. A local
renin-angiotensin system in the human pancreas has been
mapped, [14, 15] as a system that could influence pancre-
atic physiology and pathophysiology [16, 17]. Experimen-
tally, the ARB losartan reduces the inflammation in
induced acute pancreatitis among rats [18–20]. Previously
we have performed a small randomized clinical trial,
investigating the effect of losartan on pancreatic hyperen-
zymemia following endoscopic retrograde cholangio-
pancreatography [21]. However, in our study we saw no
differences between the groups, but the conclusion was
hampered by lack of statistical power.
Our group performed a nested case–control study
within a cohort of hypertension patients in the United
Kingdom, suggesting a non-significant risk reduction of
acute pancreatitis among users of ARB [22]. Also,
cardiovascular disease per se increased risk of acute pan-
creatitis in a previous report [23].
Methods
Our aim in this study was to elucidate the association
between ARB with regard to risk of acute pancreatitis,
by degree of severity, in a population-based case–control
study, taking into account the inherent risk increase that
these drug users have due to the indication of the anti-
hypertensive medication.
Study design
A Swedish nationwide, population-based case–control
study was performed during January 1st 2006 to December
31st 2008. The source population was defined as all
Swedish residents aged 40 to 84 years during the study
period. Data on emigration, cancer and death was used for
censoring to restrict the study cohort, and was obtained
from the Register of the Total Population, the Cancer
Register and the Causes of Death Register, respectively. We
performed our case–control study nested in this study co-
hort. The Swedish Patient Register was used to identify
cases of acute pancreatitis and provided data on comorbid-
ity (concomitant diseases, defined below). The Register of
the Total Population was used to select controls from the
general population [24]. The resulting patients constituted
the study population used in all subsequent analyses.
Individual data on drug exposure among cases and con-
trols was collected from the Prescribed Drug Register in
Sweden [25]. Information about highest achieved formal
educational level was received from the National Education
Register The Swedish personal identity number, a unique
10-digit figure assigned to all Swedish residents, were used
to link all study participants in the registers [26]. The
Regional Ethical Review Board in Stockholm, Sweden
approved the study.
Patient register
The Patient Register [27] comprises information on all
in-hospital care and outpatient specialist care in Sweden,
including codes for diagnoses and surgical procedures.
The Patient Register contains main and secondary
discharge diagnoses registered according to the Inter-
national Statistical Classification of Diseases and Related
Health Problems [ICD]) codes for each occasion of in-
hospital care, and has a complete nationwide coverage
of in-patient data since January 1, 1987, and complete
outpatient specialist care data since 2001. The positive
predictive value of having a coding of acute pancreatitis
in the Patient Register was 98% according to a recent
validation study from our group, [28] thus indicating
good validity of this diagnosis in the used register. All
hospitalizations and episodes of care were registered
with regard to length of stay, which was used as a proxy
for severity of pancreatitis, based on established criteria
for acute pancreatitis [29, 30].
Prescribed drug register
From 1st of July 2005 the Prescribed Drug Register
includes the personal identity number and detailed in-
formation on all drugs that are prescribed and dispensed
from all pharmacies in Sweden. In the register, informa-
tion on each prescription includes strength and amount
of the drug. Moreover, the register notes the drug’s
dispensing date, and a free text section where the daily
dose is recorded. The unique drug substance is recorded
according to the Anatomical, Therapeutic, Chemical
(ATC) classification [31].
Case and control identification
Cases were defined as persons in the study cohort having
a first time acute pancreatitis as a discharge diagnosis,
according to the 10st revision of the ICD, i.e., K85, in the
Patient Register during 2006 to 2008. Cases were further
subdivided by etiology: acute pancreatitis related to:
1) Alcohol (alcohol related disease, before or at index
occasion (291, 303, 305A, 357 F, 425 F, 535D, 571A,
571B, 571C, 571D, or 980 in the Swedish version of
ICD-9, or E244, F10, G312, G621, G721, I426, K292,
K70, K852, O354, or T51 in ICD-10, or drugs used
to treat alcohol dependence (ATC code N07BB).
2) Biliary disorders (ICD-10 K85.1 or having a gallstone
related disease (ICD-10 K80, K81) or surgical
gallbladder removal recorded at index occasion
(ICD-10 procedural codes JKA20-21), and not
alcohol pancreatitis.
3) Other type of pancreatitis, neither 1 nor 2.
Control subjects were randomly selected from the general
population according to the principle of frequency-based
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density sampling, matched for age, sex, and calendar year
using the Register of the Total Population. Medical condi-
tions and surgical procedures were assessed through
recorded hospitalizations or outpatient visits according to
the Patient Register since 1987 or dispensed prescription
since July 1st 2005. Medical drug exposure was related to
an index date assigned to all study subjects. For cases, index
date was set to be the date of admission for acute pancrea-
titis. For controls, the index date was the randomly assigned
date within the study period. Cases and eligible controls
with a previous cancer, apart from non-melanoma
cancers of the skin, or any pancreatic disease (K85,
K86, K87 [ICD-10], and 577 [ICD-9]) recorded in the
Patient Register before the study started were excluded.
Exposure to angiotensin II receptor blockers
Dispensed drug prescriptions of ARB were identified by
their specific ATC codes (C09C, C09D) in the Prescribed
Drug Register. Only exposure prior to index date was
considered in the study. We assumed that a prescription
normally lasted 114 days of drug usage, allowing a 14-
day margin for prescription renewal. Drug exposure was
defined as current or past if the drug had been dispensed
from 0 to 114, and 115–180 days, respectively in relation
to index date. The absence of a prescription or pre-
scription > 180 days before index date was classified
as non-use.
The duration of ARB usage was analysed in the following
way: current users was based on the number of days
elapsed since the first prescription of ARB. Duration was
divided into recent user, first prescription less than 90 days;
3–6 months; 6–12 months, and past usage.
Statistical analysis
The relative risk of acute pancreatitis was estimated by
unconditional logistic regression, used to calculate odds
ratios (OR) with 95% confidence interval (CI). The selec-
tion of variables was partially based on a priori decision
regarding known risk factors as potential confounding
factors, i.e. gallstone disease, alcohol related disease,
level of education, type 2 diabetes and chronic obstruct-
ive pulmonary disease (as a proxy for smoking). Also, to
evaluate the potential for confounding by indication, we
added presence of cardiovascular disorder, as defined in
a previous paper ([23]). In addition, added a comorbidity
index, based on number of distinct medications, defined
below.
This resulted in three different models that were ana-
lysed by the logistic regression. First, model 1 included
the matching variables i.e. sex, age (in categories 40–49,
50–59, 60–69, 70–79, 80–84 years) and calendar year.
Next, presence of any cardiovascular disorder (CVD)
[23] (Yes or No) was introduced to act as a proxy for se-
verity of indication for ARB and ACE-inhibitors, named
Model 2. Finally, the following variables were included
in the full model 3: 1) a general co-morbidity index mea-
sured by number of distinct medications, [23, 32] a score
defined as the sum of unique ATC codes (based on the
first 7 digits), dispensed during the last 6 months from
index date, and divided into categories (0–1, 2–4, 5–9,
10–14, and ≥15 prescriptions). 2) Education level divided
into three categories of highest attained education: elem-
entary school, secondary school, university studies, and
one category for missing data. 3) Alcohol related
diseases present before index date (see ICD codes above)
4) Gallstone disease recorded before index date, see
specification of ICD codes. 5) Chronic obstructive pul-
monary disorder (491, 492, or 496 in ICD-9, or J41, J42,
J42, J44 in ICD-10). 7) Type 2 diabetes (250 in ICD9, or
E10-E14 in ICD10, or anti-diabetic medication (ATC
code A10). To further assess the effect of confounding
by indication, we separately analysed the association
angiotensin-converting enzyme (ACE)-inhibitors (ATC
codes C09A and C09B) and acute pancreatitis. The
severity of pancreatitis was classified based on number
of days in-hospitalised: 1–3 days, 4–7, and >7 corre-
sponding to mild, moderate, and severe form of acute
pancreatitis, respectively. Moreover, we made a sub-
analysis on any use of anti-hypertensive drugs based on
ATC-codes; ARB, ACE-inhibitors, beta-blockers (C07),
calcium channel blockers (C08), and diuretics (C03).
The statistical software Stata®, version 11 (StataCorp,
Texas, USA) was used for statistical analysis.
Results
Study participants
During follow-up, 6,161 cases of first-time acute pan-
creatitis were identified, rendering a crude incidence of
22 per 100,000 person-years (data not shown). From the
study cohort, 61,637 persons were randomly selected as
controls. Some characteristics of the study participants
are described in Table 1. Men were slightly overrepre-
sented among cases of acute pancreatitis. The ratio of
university education was slightly lower among cases com-
pared to controls. The median number of medications
was higher among ARB users, 5 vs. 4 among controls
(data not shown).
Angiotensin II receptor blockers and risk of acute
pancreatitis
The association between exposure to angiotensin II
receptor blockers and acute pancreatitis is displayed in
Table 2. Current users of angiotensin II receptor blockers
had an elevated OR of 1 · 18 (95% CI 1 · 08–1 · 30) of acute
pancreatitis in the crude model with adjustment for
matching variables. In the next step, adjusting for
underlying CVD, the risk was estimated to be de-
creased; OR = 0 · 82, 95% CI 0 · 74–0 · 90. Moreover,
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usage of angiotensin II receptor blockers showed a
decreased OR of 0 · 77 (95% CI 0 · 69–0 · 86) for acute
pancreatitis, compared to non-users adjusted for the
full model 3 (Table 2). Also, the results regarding
type of ARB and risk of acute pancreatitis is shown
in Additional file 1: Table S1A.
We have analysed the effect of duration of ARB usage
and found that current users with more than 6 months
of usage, had lower OR of 0.77 with 95% CI 0.70–0.86,
compared to recent users with an OR of 1.04, 95% CI
0.68–1.58 (Additional file 1: Table S1B-C).
Table 3 presents the association between ARB and the
severity of pancreatitis. Notably, the risk was reduced for
all severities of acute pancreatitis, e.g. the risk for severe
acute pancreatitis was significantly reduced among ARB
users with a fully adjusted OR 0 · 71, 95% CI 0 · 59–0 · 85,
compared to non-users.
Stratifying acute pancreatitis by etiology resulted in
similarly negative association between angiotensin II re-
ceptor blockers and gallstone related, (OR = 0 · 67, 95%
CI: 0 · 57–0 · 78) alcohol related (OR = 0 · 50, 95% CI:0 ·
37–0 · 68), and other acute pancreatitis (OR = 0 · 77, 95%
CI :0 · 67–0 · 88) (Additional file 2: Table S2).
By restricting the analysis to only users of cardiovascu-
lar drugs there was a significant risk decrease, adjusting
for matching factors (OR 0 · 81, 95% CI 0 · 74–0 · 90),
and in the fully adjusted model (OR 0 · 84, 95% CI 0 ·
75–0 · 92). (Additional file 2: Table S3).
Exposure to angiotensin-converting enzyme inhibitors
and risk of acute pancreatitis
Current use of ACE inhibitors was associated with an
increased OR of acute pancreatitis in the full multi-
variable adjustment (OR = 1 · 11, 95% CI: 1 · 01–1 · 21)
(Table 2). In the Additional file 2: Table S3, we analysed
the effect of ACE usage within the cohort of cardiovas-
cular/anti-hypertensive medications, and noticed an in-
creased risk (adjusted OR 1 · 31, 95% CI 1 · 21–1 · 43).
Discussion
This study suggests that usage of ARB might be associ-
ated with a lower risk of acute pancreatitis.
ARB users had more comorbidity than non-users, such
as cardiovascular disorders, which entail an increased
risk, [23] acting as a potential confounding factor. This
could explain why the risk estimate adjusting for only
the matching variables was in fact increased. However,
we have scrutinized this connection in several ways; first,
after adjusting for cardiovascular disorders, which have
been shown to increase risk of acute pancreatitis in a
previous paper [23]. After this adjustment, which was a
way of taking confounding by indication into account,
the association between ARB and acute pancreatitis was
negative. Thus, indicating a potential protective effect
for ARB. From the outset, we expected comorbidity in
general to be a potential confounding factor relying on
previous research and therefore included a comorbidity
index, based on number of individual medications
[23, 32]. Number of distinct medications had a large im-
pact on the estimated relative risk of acute pancreatitis
both in the stratified analysis (data not shown), and as a
covariate in the multivariable regression model indicating
the importance of comorbidity as a confounding factor.
Second, we performed an analysis restricted to users of
any cardiovascular/antihypertensive drug, and in this
subsample looked into the association between ARB and
acute pancreatitis. The protective association was present
in the model adjusting for matching variables, suggesting
that in comparison to other hypertensive patients
Table 1 Basic characteristics among case patients with acute
pancreatitis and matched control persons
Exposure Controls Cases
N (%)* N (%)*
Total 61,637 (100) 6,161 (100)
Calendar year
2006 19,963 (32) 1,996 (32)
2007 20,728 (34) 2,071 (34)
2008 20,946 (34) 2,094 (34)
Sex
Male 33,892 (55) 3,387 (55)
Female 27,745 (45) 2,774 (45)
Age
40–49 10,562 (17) 1,055 (17)
50–59 13,978 (23) 1,397 (23)
60–69 16,590 (27) 1,659 (27)
70–79 13,908 (23) 1,391 (23)
80–84 6,599 (11) 659 (11)
Education level
Elementary school 21,896 (36) 2,464 (40)
Secondary school 24,016 (39) 2,455 (40)
University studies 14,769 (24) 1,099 (18)
Missing data 956 (2) 143 (2)
Alcohol related disease 1,549 (3) 682 (11)
Gallstone disease 2,595 (4) 2,246 (36)
Chronic obstructive pulmonary disease 1,328 (2) 326 (5)
Number of distinct medications
0–1 25,373 (41) 1,468 (24)
2–4 16,953 (28) 1,665 (27)
5–9 13,656 (22) 1,851 (30)
10–14 4,252 (7) 781 (13)
≥ 15 1,403 (2) 396 (6)
*Percentages were rounded; hence the sum could be more or less than 100
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prescribed other drugs, the relative risk of ARB was
decreased in contrast to the increased risk associated with
ACE-inhibitors. (Additional file 2: Table S3).
Additionally, to evaluate the risk of confounding by
indication, we compared the result for ARB with ACE-
inhibitors. ACE-inhibitors have similar indications, but
for which we did not hypothesize a protective relation-
ship of acute pancreatitis. In the full multi-variable
model a positive association for ACE-inhibitors was
found. However, ARB use was negatively associated with
acute pancreatitis after adjustment in the full multi-
variable model. Hence, this supports the main finding of
a separate and potentially protective association between
ARB and acute pancreatitis, and also reduces the risk of
confounding by indication.
Also, when we evaluated the effect of degree of severity
of pancreatitis, as shown in Table 3, the effect of ARB was
seen across all severities of acute pancreatitis.
The duration of ARB use seemed to be important as
indicated by the lower risk seen in users with more than
6 months of usage. We believe that the effect of ARB
usage is a long-term effect reducing inflammation and
thereby increasing the threshold of initiating an episode
of pancreatitis. Regarding dosage, our data set did not
include such data, but subsequent studies need to inves-
tigate this issue.
Previously, we carried out a study in a primary care
cohort of hypertensive patients in the United Kingdom,
[22] which suggested a statistically non-significant
decreased risk of acute pancreatitis in subjects exposed
Table 2 Exposure to angiotensin II receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors and their relative risk for
acute pancreatitis estimated by odds ratio (OR) with 95% confidence intervals (CI)
Exposure Controls Cases Model 1a Model 2b Model 3c
N (%) N (%) OR 95% CI OR 95% CI OR 95% CI
Total 61,637 (100) 6,161 (100)
ARB
Never use 56,542 (92) 5,571 (90) 1 (reference) 1 (reference) 1 (reference)
Current use 4,715 (8) 548 (9) 1 · 18 (1 · 08–1 · 30) 0 · 82 (0 · 74–0 · 90) 0 · 77 (0 · 69–0 · 86)
Past use 380 (1) 42 (1) 1 · 13 (0 · 82–1 · 55) 0 · 77 (0 · 74–0 · 90) 0 · 70 (0 · 49–1 · 01)
ACE-inhibitors
Never use 55,073 (89) 5,080 (82) 1 (reference) 1 (reference) 1 (reference)
Current use 6,067 (10) 987 (16) 1 · 82 (1 · 69–1 · 96) 1 · 16 (1 · 07–1 · 26) 1 · 11 (1 · 01–1 · 21)
Past use 497 (1) 94 (2) 2 · 11 (1 · 69–2 · 63) 1 · 37 (1 · 09–1 · 72) 1 · 24 (0 · 95–1 · 60)
aAdjusting for sex, age and calendar year. bAs Model 1 + presence of cardiovascular disorder
cAdjusting for sex, age, calendar year, education, alcohol related disease, gallstone disease, chronic obstructive pulmonary disease, diabetes, cardiovascular
disorder, and number of distinct medications, Angiotensin-converting enzyme (ACE)-inhibitors and ARB
Table 3 Exposure to angiotensin receptor blockers (ARB) and severity of acute pancreatitis, estimated by odds ratios (OR) with 95%
confidence intervals (CI)
Exposure Controls Mild acute pancreatitis Moderate acute pancreatitis Severe acute pancreatitis
N (%) N (%) N (%) N (%)
Total, n (%) 61,637 (100) 2,783 (100) 1,542 (100) 1,814 (100)
ARB 56,542 (92) 2,514 (90) 1,403 (91) 1,632 (90)
Never use
Current use 4,715 (8) 249 (9) 131 (8.5) 168 (9)
Model 1 OR (95% CI) 1 (Reference) 1 · 25 (1 · 10–1 · 44) 1 · 08 (0 · 90–1 · 30) 1 · 18 (1 · 00–1 · 39)
Model 2 (OR (95% CI) 0 · 86 (0 · 75–0 · 99) 0 · 73 (0 · 61–0 · 88) 0 · 76 (0 · 64–0 · 89)
Model 3 OR (95% CI) 0 · 81 (0 · 70–0 · 94) 0 · 71 (0 · 58–0 · 87) 0 · 71 (0 · 59–0 · 85)
Past use 380 (1) 20 (0.5) 8 (0.5) 14 (1)
Model 1 OR (95% CI) 1 (Reference) 1 · 24 (0 · 79–1 · 95) 0 · 82 (0 · 41–1 · 66) 1 · 23 (0 · 72–2 · 10)
Model 2 OR (95% CI) 0 · 85 (0 · 54–1 · 33) 0.56 (0.28–1.13) 0 · 79 (0 · 49–1 · 35)
Model 3 OR (95% CI) 0 · 75 (0 · 46–1 · 22) 0.53 (0 · 26–1 · 08) 0 · 75 (0 · 42–1 · 29)
1) Adjusting for sex, age and calendar year
2) Adjusting for sex, age, calendar year and presence of cardiovascular disorder
3) Adjusting for sex, age, calendar year, education, chronic obstructive pulmonary disease, diabetes, alcohol related disease, cardiovascular disorder, and number
of distinct medications
Bexelius et al. BMC Gastroenterology  (2017) 17:36 Page 5 of 7
to angiotensin II receptor blockers, but not among users
of other anti-hypertensive medications. The sample size
of that study was smaller and the hypertension cohort
was different compared to the present report. The main
advantages of the present study were the large sample-
size, and the population-based design reducing chance
errors and selection bias, respectively. The Prescribed
Drug Register and the Patient Register gave unbiased ac-
cess to the study exposure, outcome and some potential
confounders. The validity of the outcome measurement
was high, according to our recent validation study [28].
Some potential drawbacks warrant further comments.
A common problem in observational studies is lack of
precision in measuring exposure. Our cut-off for current
use of 114 days was chosen based on the mean length of
a prescription of 100 days, allowing a 2 weeks margin
for renewal of prescription to index date. To address the
potential misclassification of exposure, two alternative
approaches were used. First, the cut-off was changed to
90 days for current use. Second, information on dosage
from the manual review was used to calculate the actual
prescription length in relation to index date. Neither of
the two approaches changed the association substantially
between angiotensin II receptor blocker and acute
pancreatitis (data not shown). Still, some misclassifica-
tion of exposure could remain, contributing to the non-
significant decreased risk seen among past users.
Another potential weakness is incorrect handling of con-
founding factors. Alcohol consumption was measured
indirectly, i.e. based on diagnosis of alcohol related dis-
orders in the present report. In a recent study [28] from
our group validating the acute pancreatitis diagnosis and
classifying the type of pancreatitis after a manual chart
review, we found a similar ratio of alcohol related pan-
creatitis using our proxy variable; alcohol related disease.
This suggests that our measurement of alcohol exposure
is reliable. We also adjusted for the usage of anxiolytics,
which is associated with high alcohol consumption. This
adjustment did not affect the OR of ARB and acute
pancreatitis (data not shown). In addition, to evaluate
the potential confounding effect of tobacco smoking, an
established risk factor of acute pancreatitis, [33] we
adjusted for chronic obstructive pulmonary disease, a
disease closely related to tobacco smoking. This adjust-
ment did not substantially affect the risk estimate of
ARB and acute pancreatitis, why tobacco smoking was
not considered an important confounding factor for this
association.
Furthermore, confounding by socioeconomic position
could be present, as there has previously been described
a lower exposure to angiotensin II receptor blockers in
low educated groups [34]. However, adjusting for socio-
economic position did not substantially affect our risk
estimates contradicting such confounding.
Angiotensin II has been proposed to be a pro-
inflammatory mediator, [35] hence blocking the main
receptor pathway would be beneficial. Angiotensin II
receptor blockers could also reduce ischemia and conse-
quently inflammation [16]. Recently losartan showed
reduced biomarker level for pancreatic inflammation in an
experimental model [36]. Although poorly understood in
the human pancreas, this could explain our protective
finding, in addition to animal studies on experimentally
induced pancreatitis [18–20, 37].
Conclusions
In conclusion, this Swedish population-based case–control
study suggests a protective effect of angiotensin II receptor
blockers on the risk of developing acute pancreatitis.
Further studies are warranted before a causal association
can be established.
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